Biotech By Matthew Herper Grail, a deep-pocketed startup, shows ‘impressive,’ if early, results for cancer blood test
Biotech By Adam Feuerstein Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients
Pharma By Matthew Herper Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs
Biotech By Adam Feuerstein Moderna makes ASCO debut with an early look at a personalized cancer vaccine
Biotech By Matthew Herper Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t
Health By Matthew Herper The Affordable Care Act erased a racial disparity in cancer care, a new study says
Biotech By Adam Feuerstein Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study
Biotech By Adam Feuerstein Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show
The Readout LOUD By Adam Feuerstein and Matthew Herper Listen: A special episode from the halls of the ASCO meeting
Biotech By Adam Feuerstein and Matthew Herper What you missed at ASCO? A lot, as cancer research hastens on
Biotech By Adam Feuerstein At ASCO, targeted lung cancer drugs shrink tumors caused by rare genetic mutations
Biotech By Matthew Herper Tempus, a well-funded company run by a Groupon billionaire, wants to get patients into clinical trials
Biotech By Matthew Herper Turning Point Therapeutics drug shows benefits for patients with rare lung cancer gene
Biotech By Jonathan Saltzman — Boston Globe Epizyme seeks early approval for drug to treat ultra-rare tumors
Pharmalot By Ed Silverman More new cancer therapies are being launched than ever before, but spending is skyrocketing
Health By Sharon Begley Cancer patients keep getting aggressive end-of-life treatment, despite lack of benefit
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Immunomedics abstract booted from cancer conference